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Objectives: Create trustworthy, rigorous, national clinical practice 
guidelines for the practice of pediatric donation after circulatory 
determination of death in Canada.
Methods: We followed a process of clinical practice guideline devel-
opment based on World Health Organization and Canadian Medical 
Association methods. This included application of Grading of Rec-
ommendations Assessment, Development, and Evaluation methodol-
ogy. Questions requiring recommendations were generated based on 
1) 2006 Canadian donation after circulatory determination of death 
guidelines (not pediatric specific), 2) a multidisciplinary symposium of 
national and international pediatric donation after circulatory determi-
nation of death leaders, and 3) a scoping review of the pediatric dona-
tion after circulatory  determination of death literature. Input from these 
sources drove drafting of actionable questions and Good Practice 
Statements, as defined by the Grading of Recommendations Assess-
ment, Development, and Evaluation group. We performed additional 
literature reviews for all actionable questions. Evidence was assessed 
for quality using Grading of Recommendations Assessment, Develop-
ment, and Evaluation and then formulated into evidence profiles that 
informed recommendations through the evidence-to-decision frame-
work. Recommendations were revised through consensus among 
members of seven topic-specific working groups and finalized during 
meetings of working group leads and the planning committee. Exter-
nal review was provided by pediatric, critical care, and critical care 
nursing professional societies and patient partners.
Results: We generated 63 Good Practice Statements and seven 
Grading of Recommendations Assessment, Development, and 
Evaluation recommendations covering 1) ethics, consent, and 
withdrawal of life-sustaining therapy, 2) eligibility, 3) withdrawal of 
life-sustaining therapy practices, 4) ante and postmortem interven-
tions, 5) death determination, 6) neonatal pediatric donation after 
circulatory determination of death, 7) cardiac and innovative pedi-
atric donation after circulatory determination of death, and 8) imple-
mentation. For brevity, 48 Good Practice Statement and truncated 
justification are included in this summary report. The remaining 
recommendations, detailed methodology, full Grading of Recom-
mendations Assessment, Development, and Evaluation tables, and 
expanded justifications are available in the full text report.
Conclusions: This process showed that rigorous, transparent clini-
cal practice guideline development is possible in the domain of 
pediatric deceased donation. Application of these recommenda-
tions will increase access to pediatric donation after circulatory 
determination of death across Canada and may serve as a model 
for future clinical practice guideline development in deceased 
donation. (Pediatr Crit Care Med 2017; 18:1035–1046)
Key Words: clinical practice guidelines; deceased organ donation; 
donation after circulatory determination of death; end-of-life care; 
ethics
Since the publication of the 2006 consensus Canadian recommendation (1), donation after circulatory deter-mination of death (DCD) has become an increasingly 
frequent path to donation for adults (2). Implementation of 
pediatric DCD (pDCD) has lagged behind. According to 2014 
data from Canadian Blood Services, DCD represented 21% of 
total national deceased donation, but pDCD made up only 8% 
of pediatric deceased donation. The purpose of this document 
is to provide rigorously developed, evidence-based guidelines 
that centers can use to develop pDCD in Canada.
One of the methods proposed by donation experts to 
improve pDCD practice is standardization and evidence-based 
recommendations (3). Current pDCD practice varies by juris-
diction and center (3, 4), likely as a result of the fact that no 
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national or international guidelines specifically address pDCD. 
As detailed below, we have employed a rigorous guideline 
development methodology, including an extensive literature 
review (5) and multidisciplinary consultation to create recom-
mendations for all aspects of pDCD.
METHODS
The guideline was developed by a multidisciplinary guideline 
development committee that included seven topic-specific 
working groups (WGs). Two patient-family partners, profes-
sional society partners, and an international expert provided 
external review. Funding was provided by Canadian Blood Ser-
vices. No guideline development member disclosed any financial 
conflicts of interest with for-profit entities, though several were 
or are paid donor physicians associated with governmental not-
for-profit organ donation organizations (ODOs), and others 
have active research and academic activities in organ donation.
The guideline development committee adhered to a 
rigorous development process based on the Grading of 
Recommendations Assessment, Development, and Evaluation 
(GRADE) methods and consistent with recommendations 
from several national and international bodies (6–9). The 
scope of the guideline included only controlled pDCD (e.g., 
after planned withdrawal of life-sustaining therapies [WLSTs]). 
Specifically, we defined uncontrolled pDCD, or donation after 
cardiac arrest outside of a WLST setting, to be outside the scope 
of these guidelines. The guideline development committee and 
WGs judged the quality of evidence and created evidence-to-
decision tables before making either “strong” or “conditional” 
recommendations according to the GRADE approach (10). 
In cases where the guideline development committee felt that 
there was insufficient evidence or the balance of benefits and 
harms was likely neutral, no recommendation was made.
In addition to GRADEd recommendations, the guideline 
development committee formulated Good Practice Statements 
(GPSs) in cases where there was a large body of indirect evi-
dence strongly supporting the net benefit of the recommen-
dation or there was no reasonable comparator (11). Full 
consensus by all guideline development committee and WG 
members was achieved for all recommendations.
This report is a summary that does not include all the rec-
ommendations or the justifications. For all recommendations, 
justifications, complete GRADE tables for actionable recom-
mendations, and a comprehensive description of the guideline 
development process, please refer to the full report available at 
http://www.organsandtissues.ca/s/english-expert/leading-prac-
tices-public-awareness-and-education. For a global review of the 
pDCD literature, please refer to the associated scoping review (5).
RECOMMENDATIONS
Ethics and WLST
Good Practice Statements.
1) pDCD is a medically and ethically viable pathway to pro-
vide access to deceased organ donation.
2) The option of deceased donation, including pDCD, should 
be routinely incorporated into end-of-life (EOL) care.
3) Healthcare systems should establish processes to ensure 
pDCD access.
4) Throughout the WLST and donation process, healthcare 
professionals must respect the dignity of the dying process.
5) The discussions and process of deceased donation should 
respect the beliefs and values of the surrogate decision mak-
ers and other loved ones involved.
6) In recognition of diversity of perspectives on pDCD, health-
care professionals should be allowed to conscientiously 
object to participation in pDCD.
 a)  In the case of healthcare professional objection, institu-
tions should work to honor the surrogate decision mak-
ers’ wishes to donate.
Justification.  The option to offer DCD as part of EOL care 
is universally supported by professional societies and ODOs 
that have examined the issue (1, 12–15), including two specific 
endorsements from the American Academy of Pediatrics (16, 17). 
Despite this broad consensus, some authors have expressed con-
cerns around ethical aspects of pDCD (18, 19). Some individuals 
within the healthcare team may have differing views on the mean-
ing and permissibility of deceased organ and tissue donation 
(OTD) based on societal, cultural, religious, and other personal 
beliefs (20). These concerns justify the above recommendation to 
allow conscientious objection by healthcare professionals to not 
participate in pDCD, consistent with other policy and position 
statements (12, 17, 21). However, considering the important role 
donation can play in the lives of donor families, these objections 
should not prohibit substitute decision makers and families from 
participating in pDCD if they so desire, which is why we empha-
size that institutions should work to accommodate these requests 
using the principles of effective referral.
Decision-Making Process for WLST
Good Practice Statements.
7) The decision to pursue WLST must not be influenced 
by donation potential and should proceed according to 
accepted medical practices.
8) The ODO, organ recovery, and transplant team must not 
be involved in the decision to pursue WLST or have direct 
contact with surrogate decision makers before WLST deci-
sions are finalized.
 a)  Treating teams may contact ODOs to assess eligibility prior 
to the decision to pursue WLST, as long as there is no direct 
contact between the ODO and surrogate decision makers.
9) The decision to pursue WLST should be made before 
any discussion of OTD that is initiated by healthcare 
professionals.
 b)  If surrogate decision makers initiate organ donation dis-
cussions prior to the decision to pursue WLST, informa-
tion may be provided, but consent discussions should be 
deferred until WLST decisions have been finalized.
Weiss et al
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10) Safeguards should be in place to ensure that mitigation of 
conflict of interest for the case where a patient who is a 
potential donor and a patient who is a potential recipient 
are being cared for in the same care unit.
Justification. In order to avoid real or perceived conflicts of 
interest, decisions pertaining to OTD must be kept as separate 
as possible from decisions regarding WLST. As is universally 
supported in the literature, the above recommendations sup-
port that WLST decision-making follow established, best prac-
tices regardless of pDCD potential (12–14, 16, 17, 22–26).
One area we believe merits particular attention is when a 
patient who is a potential donor and a patient who is a poten-
tial recipient are simultaneously cared for in the same unit. This 
possibility is more likely in pediatric than adult practice given the 
smaller number of recovery and transplant hospitals. We acknowl-
edge this as a potential conflict and encourage systems to ensure 
ethical safeguards if the substitute decision maker is motivated to 
pursue donation in this setting. Measures to mitigate this poten-
tial conflict will depend on local context but could include ethics 
consultation or a second opinion from an uninvolved clinician.
Eligibility
Good Practice Statements.
11) Individual transplant programs, in collaboration with 
pediatric and neonatal healthcare professionals and 
ODOs, should determine criteria for donor eligibility, lim-
its of warm, and cold ischemic time. Special consideration 
should be given for neonatal patients who are potential 
donors.
12) Coroners must be notified prior to donation proceedings 
according to provincial laws. If coroner evaluation and 
approval to pursue pDCD is required, this should be done 
prior to consent discussions with the surrogate decision 
makers.
Justification. We chose to limit our recommendations related 
to pDCD eligibility. Further national recommendations will 
require input from multidisciplinary groups, including trans-
plant surgeons and physicians caring for recipients of pDCD 
organs, in order to form organ-specific recommendations. Cur-
rent recommendations from groups such as the Canadian Soci-
ety of Transplantation should inform these discussions, including 
those on high-risk donors (27). These criteria will be subject to 
change based on center experience, further research, and recom-
mendations from organ-specific transplantation groups.
Consent for pDCD
Good Practice Statements.
13)  Consent discussions for pDCD can include members of 
the care team, representatives of the ODO, or healthcare 
professionals from both groups.
 a)  As stated in GPS 9 above, all discussions of organ dona-
tion initiated by healthcare providers must be deferred 
until after WLST decisions are finalized.
14)  The person or team discussing consent should have exten-
sive knowledge of the local process and should clearly 
identify their institutional affiliations.
15)  Consent conversations with surrogate decision makers 
should include the opportunity to discuss beliefs and val-
ues around all aspects of pDCD, including death and death 
determination.
16)  At minimum, the following information should be pro-
vided to surrogate decision makers regarding the pDCD 
process:
 a)  Logistics of the process, including that WLST may be 
delayed due to pDCD logistics, and where WLST will 
occur,
 b)  The procedures and methods of determining death, 
including that these practices conform to accepted 
medical and legal standards,
 c) Which organs are potentially eligible for recovery,
 d)  That consenting for pDCD does not guarantee organ 
recovery or transplantation,
 e)  If organ recovery is not possible, tissue donation may 
remain an option,
 f)  How EOL care would proceed if they decline organ 
donation or if recovery does not occur after attempted 
donation,
 g)  That the treating team has no influence over alloca-
tion, which may include allocation to adult or pediatric 
recipients,
 h)  That surrogate decision makers will be supported if 
they consent to or decline pDCD, and
 i)  That consent can be withdrawn at any time, including 
after the determination of death.
 17)  Tests and interventions prior to death (antemortem inter-
ventions) to facilitate donation in pDCD require specific 
and informed consent from the surrogate decision makers 
for each intervention.
 a)  Antemortem interventions should only be undertaken 
with disclosure and consideration of risks and benefits 
to the patient who is a potential donor.
 b)  Antemortem interventions should not be intended to 
hasten death.
 c)  Antemortem interventions should pose no more risk 
to the patient than routine intensive care practices.
 18)  Antemortem interventions should be recognized as pro-
viding nonmedical benefit to the patient who is a poten-
tial donor by allowing realization of interest and intent to 
donate despite the fact that these interventions provide no 
medical benefit to the patient who is a potential donor. 
This justifies surrogate decision maker’s authority to con-
sent to interventions that pose no increased risk beyond 
routine intensive care practices despite no medical benefit 
to the patient who is a potential donor.
Justification. How best to engage in consent discussions 
was carefully considered for these recommendations. There 
is significant practice variability concerning which healthcare 
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professionals should be present during consent discussions. 
Regardless of whether an ODO representative is present during 
the consent request, we recommend that person have detailed 
knowledge of the local processes and procedures. Further dis-
cussion of training requirements for people requesting consent 
can be found under Actionable Recommendation 1. Further-
more, the stage in the EOL pathway at which ODOs are to be 
notified varies across jurisdictions, often related to require-
ments of mandatory reporting laws. The laws and local prac-
tices of reporting of a patient who is a potential donor should 
be carefully considered when establishing a pDCD protocol.
The understanding of consent for pDCD also requires an 
understanding of the distinction between consent for interven-
tions before (ante) and after (post) mortem. It is outside the 
scope of these guidelines to extensively review the legal frame-
work governing pDCD consent, but deceased donation in 
Canada is governed by provincial tissue gift legislation. Similar 
to the concept of “authorization” used more commonly in the 
United States, permission to proceed with donation under gift 
acts is different from, and legally less demanding than informed 
consent for treatment of a living patient (28). Consideration of 
benefit or harm posed to the patient, which forms the basis 
of informed consent to treatment, cannot be applied in the 
context of postmortem organ recovery any more than it can 
applied to the processes of cremation or embalming (28).
pDCD, however, includes both authorization for postmor-
tem organ recovery and consent for antemortem interventions 
that do require full informed consent. A question that is often 
raised in pDCD considerations is if substitute decision makers 
or families can give valid consent for a procedure that might 
cause harm or discomfort to the donor while providing medi-
cal benefit only to the organ recipient. Several authors (22, 29, 
30), including the 2013 American shared position statement 
from the American Thoracic Society, the Society for Heart and 
Lung Transplantation, the Society of Critical Care Medicine, 
the Association of Organ Procurement Organizations, and the 
United Network of Organ Sharing (12), answer in the affirma-
tive. Their rationale is that if the process presents potential risk 
of harm that is similar to routine intensive care practices, and 
the procedure is in line with parental values, an assumption of 
altruism is legitimate (22, 29). The benefit to the patient who is 
a potential donor is therefore allowing donation to proceed in 
order to fulfill family or surrogate desire to donate, and it is this 
benefit that justifies assumption of risk without direct medical 
benefit. This is consistent with the ethical reasoning support-
ing children’s participation in medical research where there is 
no hope for direct benefit to them. Furthermore, not allowing 
patients’ substitute decision makers or families to accept this level 
of risk in order to act altruistically in this circumstance would 
limit their autonomy (21). These arguments, however, are not 
universally accepted, and others claim that altruism on the part 
of an incompetent child cannot be assumed based on parental 
values (18). We conclude that divergent opinions regarding the 
ethical acceptability of such antemortem interventions would be 
a justifiable reason for healthcare professionals to excuse them-
selves from pDCD proceedings through conscientious objection.
It is impossible to specifically recommend how to weigh 
these risks and benefits in all the nuanced situations that will 
arise for individual patients (e.g., heparin administration to a 
patient with a remote history of an intracranial hemorrhage). 
It is the responsibility of the treating team, with appropriate 
ethical oversight, to ensure that protection of the interests of 
the patient who is a potential donor remains the primary con-
cern throughout these situations.
Any test of organ eligibility or those specific for allocation 
(e.g., human leukocyte antigen matching) should be consid-
ered an antemortem test and should not be performed until 
consent for the pDCD process and required investigations has 
been obtained.
For further information regarding general best practices in 
organ donation consent, please consult the recent report from 
Canadian Blood Services (31).
Actionable Recommendation.  “Should trained profession-
als versus professionals without specific training be used for 
approaching families for consent in the setting of pediatric 
donation after circulatory death?”
19)  The panel did not make a recommendation regarding 
minimal required training of professionals approaching 
families for consent in the setting of pediatric donation 
after circulatory death.
Justification. Although several observational reports 
(32–43) suggest that trained requesting is effective at 
increasing consent rates, the only randomized controlled 
trial (44) showed no effect of involving trained ODO staff 
at the time of consent. None of these studies were exclusive 
to pediatrics or even DCD. Only one (33) of 13 references 
examined family satisfaction after the consent process as 
an outcome.
Considering the lack of conclusive evidence supporting 
benefit, and the substantial system investment that would be 
required to have trained requesters present at every consent 
conversation, we chose to not recommend for or against this 
intervention. For further information on effective requesting 
techniques in deceased donation, please refer to the recently 
published report from Canadian Blood Services (31).
Procedures for WLST in the Context of pDCD
Good Practice Statements.
20)  WLST practice should be based on established ICU or 
hospital practices, policies, and guidelines.
21) The critical care team must be responsible for patient 
management between the decision to WLST and the deter-
mination of death.
22)  The ODO, organ recovery, and transplant team must not 
be involved in any aspect of management of the dying 
process.
23) WLST may occur in the critical care unit, near the operat-
ing room, or in the operating room, as determined by sur-
rogate decision makers’ preferences, institutional logistics, 
resources, and facilities.
Weiss et al
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24) Psychosocial, spiritual, and bereavement support should 
be provided to surrogate decision makers regardless of 
WLST location.
25) Wherever WLST occurs, surrogate decision makers and 
other loved ones should be given the option to be physi-
cally present with the patient who is a potential donor 
until the determination of death is complete.
26) The organ recovery team should not be physically pres-
ent in the room until the determination of death has been 
completed and the surrogate decision makers are escorted 
from the bedside.
27) If a patient who is a potential donor is hospitalized where 
pDCD is not available, and the surrogate decision makers 
are motivated to donate, consideration should be given for 
patient transfer to a hospital that performs pDCD.
Justification. The fiduciary responsibilities of ICU clini-
cians are first and foremost to act in the best interest of his 
or her patient (12, 13, 16), and we therefore strongly support 
that in the event of a conflict in management goals between 
organ donation and optimal EOL care, care for the dying child 
should always take precedence. As universally supported in 
the published literature, WLST practices should be provided 
with minimal deviations from standard practice, including 
full support available for families (12–14, 16, 17, 21, 22, 25, 26, 
45). Our group did not specifically deliberate on the issue of 
whether the practice of surgical preparation of the patient who 
is a potential donor (sterilization of the surgical field, drap-
ing, etc.) represented acceptable contact between the recov-
ery team and the donor prior to death determination. In line 
with other recommendations, if this practice is required by the 
recovery team, it should be treated as an antemortem inter-
vention requiring specific informed consent, and the recovery 
team should in no way otherwise influence EOL care. Also if 
practiced, this contact should not alter the recommendation 
that the recovery team not be physically present in the room 
at the time of death determination, and they should leave the 
operating room after surgical preparation is completed and 
before the parents enter.
Time From WLST to Determination of Death
Good Practice Statements.
28) A maximum time limit from the start of WLST to death, 
beyond which organs will not be recovered, should be 
established in collaboration with ODOs and local trans-
plant teams.
Justification. The duration of acceptable warm ischemic 
time (WIT) should be locally informed and based on organ-
specific concerns (13, 46, 47). Current practice in most pDCD 
centers recommends WIT of 30–90 minutes, depending on the 
organ to be recovered. Adult practices may vary from 1 to 4 
hours depending on multiple factors, including limitations of 
access to operating rooms. Our guideline committee did not 
consist of transplant surgeons or posttransplantation physi-
cians who could provide meaningful expertise into the effects 
of various WIT thresholds on specific organs, and we therefore 
specifically chose not to make recommendations regarding the 
length of acceptable WIT.
Actionable Recommendation. “Should formal predictive 
tools versus no formal tool (clinical judgment) be used for 
predicting time of death within 30 or 60 minutes of WLST?”
29) The panel did not make a recommendation regarding use 
of tools to predict the time from WLST to death.
Justification. Though a prediction tool developed by Shore 
et al (48) has shown reasonable predictive value, it remains 
to be tested against clinical judgment or prospectively vali-
dated. Prediction tools cause no direct harm to a patient, may 
provide important information to the clinical team and sur-
rogate decision makers, and are low cost. The risk, however, 
is if clinicians choose whether or not to pursue donation pro-
ceedings based solely on such a tool without understanding 
its strengths and limitations. Although future iterations may 
result in improved sensitivity and specificity, we currently do 
not recommend for or against the use of death prediction 
tools.
Minimum Standards Required for Death 
Determination in pDCD
Definition of Death Used for these Recommendations. 
There is currently no Canadian federal, provincial, or territo-
rial statute mandating how clinicians determine when a patient 
is dead. As there is also no widely accepted medical standard 
from Canadian professional societies, we have chosen, for 
the purposes of this guideline, to use the following definition 
taken from recently proposed guidelines at the World Health 
Organization:
The definition of death by circulatory determination: The 
permanent loss of capacity for consciousness and all brainstem 
functions, as a consequence of permanent cessation of circulation. 
Permanence is defined as loss of function that will not resume 
spontaneously and will not be restored through intervention (49).
This definition is consistent both with current accepted 
Canadian medical practice and the definitions used in the cur-
rent clinical practice recommendations governing donation 
circulatory death in adults (1).
Good Practice Statements. The following includes a sum-
mary of current Canadian laws and practices governing 
deceased donation. These laws and recommendations should 
be understood to represent the minimum standards necessary 
to determine death. They do not preclude additional standards, 
as long as those standards are accepted prior to implementa-
tion by all stakeholders.
30) The dead donor rule must be respected within the context 
of pDCD.
31) Death must be determined by two physicians in accor-
dance with accepted medical practice.
 a)  The two physicians must confirm their determinations 
concurrently at the end of a hands-off period of obser-
vation during circulatory arrest.
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32) No physician who has active involvement in transplant 
procedures or allocation of donated organs shall take any 
part in donor death determination.
33) The minimum level of physician qualification required to 
determine death in pDCD is as follows:
 a)  They possess the requisite skills and training. A partic-
ular level of specialty certification is not required, but 
skills and training should include ability to interpret 
monitoring used.
 b)  At least one of these physicians must be an attending 
physician staff in the ICU of the patient and possess 
full and current licensure for independent medical 
practice in the relevant Canadian jurisdiction.
 c)  The second physician could be on an educational reg-
ister (e.g., residents, fellows), as long as they have the 
requisite skills and training.
34) The following criteria must be met before organ recovery:
 a)  Circulatory arrest, defined as the absence of antero-
grade arterial circulation. See actionable recommenda-
tions 37 and 38 for the specifics of how to determine 
that absence.
 b)  A hands-off period of continuous observation of cir-
culatory arrest during which no interventions are 
undertaken to facilitate donation. See recommenda-
tion below for duration of hands-off period.
 c)  At the end of this period, death is legally determined, 
and organ recovery may commence.
 35) Recovery and transplantation of the heart in pDCD is con-
sistent with the dead donor rule, as death is based on the 
permanent cessation of circulation.
36) The same criteria should apply to all potential pDCD 
donors including those undergoing withdrawal of 
mechanical circulatory support such as extracorporeal 
mechanical oxygenation (ECMO).
Justification. The definition of death used for these guide-
lines represents both current accepted Canadian practice and 
is consistent with evolving international consensus (49). The 
details of how cessation of circulation is determined and for 
how long are detailed below in actionable recommendations 37 
and 38. pDCD, practiced according to these practices and defi-
nitions, respects the dead donor rule, defined as “vital organs 
should only be taken from dead patients and, correlatively, liv-
ing patients must not be killed by organ retrieval” (50).
We have chosen to recommend that although the first phy-
sician determining death in pDCD must have a full, unre-
stricted license to practice, the second may be a trainee on an 
educational register. This recommendation considers that the 
death determination in pDCD requires skills or training that 
would be readily available to a resident or fellow undergoing 
training in a PICU or neonatal ICU (NICU). If the second 
physician is on an educational register, he or she should be 
reminded that they are not obligated to participate and that 
a decision to participate or no will not affect their evalua-
tion. Also, the second physician need not be from a certain 
specialty, as long as he or she possesses the capacity to deter-
mine death in this setting, specifically the ability to interpret 
an arterial catheter waveform tracing.
In GPS 32, active involvement in transplant procedures or 
allocation is defined as any involvement in postmortem surgi-
cal recovery procedures, discussions of which patient on the 
transplant wait list will receive the donated organs, or partici-
pation in any part of the transplantation procedure (including 
anesthesia of the recipient). Consultant physicians who might 
be involved in evaluating the patient for donor eligibility and 
might also care for a potential recipient (e.g., nephrologists) 
would be excluded from participating in the determination of 
death. As addressed in GPS 10, it is possible that intensive care 
physicians will be involved directly or indirectly with the care of 
both donor patients and those who receive transplanted organs 
from the same donor due to the limited number of PICUs in 
Canada. Ethical safeguards should be developed in these cases.
Regarding GPS 36, in the past, when DCD was more com-
monly referred to as “donation after cardiac death,” authors 
argued that determining death by irreversible loss of cardiac 
function precluded DCD cardiac transplantation (51, 52). 
However, our guidelines specifically define death as permanent 
loss of circulation in the donor. Whether the heart remains 
unresuscitated in the donor or is removed and resuscitated in 
another patient does not alter donor outcome: body and brain 
circulation remains permanently ceased in the dead donor (53). 
Thus, cardiac pDCD practiced according to these guidelines 
would respect the dead donor rule.
Actionable Recommendation. “Should arterial line versus 
palpable pulses and auscultation be used for confirmation of 
lack of anterograde circulation?”
37) We recommend that a well-functioning arterial catheter be 
used to confirm arrest of anterograde arterial circulation 
for the determination of death. (strong recommendation, 
low certainty in evidence)
Justification. Although not specific to a pDCD setting, data 
from studies designed to test clinicians ability to determine 
between low and nonpulsatile states suggest that even expe-
rienced PICU physicians commit errors (54–56). The panel 
strongly felt that palpation of pulse was an inadequate method 
to confirm lack of circulation. Arterial catheter monitoring is 
commonly used, easily interpreted, and objective. The recom-
mendation to rely on arterial catheter monitoring assumes a 
functioning and verified arterial catheter. No other confirma-
tion of loss of anterograde circulation (e.g., electrical asystole) 
is necessary when a well-functioning arterial catheter is in 
place. Although auscultation or palpation should not be used 
to confirm lack of circulation, they could be applied to verify 
that an observed flat waveform corresponds with the clinical 
state. We make no recommendation as to the required site of 
the arterial catheter.
Please see the full report for consideration of situations 
when an arterial catheter is not possible for technical reasons 
or due to surrogate decision maker refusal, including the use of 
other modalities such as echocardiography.
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Actionable Recommendation. “Should 10 minutes hands-
off time versus 5 minutes hands-off time be used for death 
determination in pDCD donors?”
38) We suggest 5 minutes of hands-off observation of arrest of 
circulation prior to determination of death. (conditional 
recommendation, very low certainty in evidence)
Justification. Currently, all Canadian adult and pediat-
ric centers performing DCD use 5-minute hands-off period. 
During this 5-minute period, also sometimes referred to as a 
“no touch” period, no healthcare professional should have any 
physical contact with the patient, and the physicians determin-
ing death should be constantly observing the method used to 
confirm absent circulation. The period of time commences 
when no visible pulsatility is observable on a well-function-
ing arterial catheter waveform or after the last evidence of 
anterograde circulation (e.g., last opening of the aortic valve 
by echocardiography). If evidence of circulation is detected 
during the 5-minute hands-off period, the observation period 
should recommence until 5 full minutes of absent circulation 
are observed. This period is longer than any reported case of 
autoresuscitation after WLST (57, 58), and organs transplanted 
after this ischemic time have acceptable outcomes (59–61). 
However, based on the low quality of the reviewed autoresus-
citation evidence and the fact that no reports compared organ 
outcomes using 5- versus 10-minute hands-off times, we chose 
to make a conditional recommendation.
Ante and Postmortem Interventions
Good Practice Statements.
Antemortem.
39) Any intervention or test that may pose discomfort to the 
patient who is a potential donor should be managed with 
analgesia and/or sedation as per standard ICU practices.
40) Consideration should be given to the timing of adminis-
tration of any antemortem pharmacologic intervention in 
order to minimize any potential risks.
Postmortem.
41) Interventions that do or may reinstitute oxygenated brain 
blood flow after death must not be performed, including 
cyclic ventilation after reintubation for lung donation.
42)  Only the organ recovery team may carry out postmortem 
surgical interventions.
Justification. The above recommendations emphasize that 
any antemortem intervention, including transfer of a patient 
who is a potential donor, carries the same requirements for 
informed consent, minimization of risk, and respect for the 
comfort of the patient as in routine care of ICU patients. Refer 
to the “Consent for Antemortem Interventions” section above 
for additional discussion.
Regarding postmortem interventions, our primary concern 
was the need to avoid interventions that might reestablish oxy-
genated brain blood flow. Absence of oxygenated brain blood 
flow is the key component of the determination of death, so 
procedures that potentially reestablish that flow could violate 
the dead donor rule. Understanding that risk, we recommend 
that tracheal reintubation is permissible as long as cyclic venti-
lation is not provided. Through cardiopulmonary interactions, 
cyclic ventilation has the theoretical risk of restoring oxygen-
ation and brain circulation, and its avoidance has been recom-
mended by other groups (12, 14).
Actionable Recommendation. “Should Heparin versus 
no anticoagulation be used for pDCD as an ante mortem 
intervention?”
43) The panel did not make a recommendation regarding 
the universal administration of heparin in the setting of 
pDCD.
Justification. Given the lack of available evidence for benefit 
in pediatric or adult patients (62, 63) and concerns regard-
ing any antemortem interventions that could cause harm to a 
patient who is a potential donor, we make no recommendation 
regarding routine antemortem heparin administration pDCD. 
If given, practices such as dose and timing of administration 
should be determined jointly by intensive care teams, ODOs, 
and transplant programs to ensure that harm to a patient who 
is a potential donor is minimized.
Actionable Recommendation. “Should regional oxygenated 
perfusion techniques versus no such techniques be used for 
improving organ outcome in controlled pDCD?”
44)  We recommend that regional perfusion not be used in the 
setting of pDCD (strong recommendation, very low cer-
tainty in evidence).
Justification. Although not practiced in Canada, other juris-
dictions have employed perfusion techniques (e.g., modified 
ECMO) that provide oxygenated blood flow to abdominal 
organs after death but prior to organ recovery, while excluding 
blood brain flow. Reports of this practice were considered indi-
rect to our question, since they were almost exclusive to adult 
donors (64–74), and often involved antemortem interventions 
such as cannulation that would be in conflict with current 
Canadian pDCD practice.
Given the low quality of the evidence reporting benefit, 
risk of the significant consequence of reestablishing brain 
blood flow through inadequate aortic occlusion, and the cost/
resources involved, we feel that regional perfusion techniques 
should not be used for pDCD (64, 73).
Although we do not recommend its use in standard prac-
tice, regional perfusion techniques could be considered as part 
of a research protocol with research ethics board approval. 
Oversight should include techniques to ensure the absence of 
brain blood flow during regional perfusion.
Actionable Recommendation. “Should bronchoscopy ver-
sus no bronchoscopy be used for ante mortem evaluation of 
lung function in potential pDCD donors?”
45) The panel did not make a recommendation for or against 
the routine use of antemortem bronchoscopy in the set-
ting of pDCD.
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Justification. Although bronchoscopy is frequently practiced 
in neurologic determination of death and DCD organ dona-
tion, its association with graft or recipient outcome in pDCD 
is not well described (75–77). We acknowledge that antemor-
tem bronchoscopy prior to controlled pDCD is likely a low 
risk procedure, but there are no published reports evaluating 
adverse events rates in this setting. This balance of consider-
ations led us to not recommend for or against antemortem 
bronchoscopy.
The possibility of postmortem bronchoscopy either in situ 
or ex vivo is unreported in the current literature but would 
likely be of similar benefit as a pretransplant bronchoscopic 
evaluation while eliminating risk conferred to the patient who 
is a potential donor.
Cardiac pDCD
Good Practice Statements.
46) Considering the lack of published experience in cardiac 
pDCD:
 a)  Cardiac transplant programs should establish criteria 
for acceptance of heart donation, ex vivo cardiac pro-
tocols, and heart allocation in pDCD,
 b)  Consideration should be given to initiate cardiac pDCD 
program as either research protocols with research eth-
ics board oversight or through programs that oversee 
innovative therapies.
Justification. Although there is minimal published experi-
ence with cardiac pDCD (78), recent innovative reports of 
adult cardiac DCD using ex vivo heart preservation suggests 
that this option may evolve as a viable clinical pathway in the 
near future (79). We considered this lack of evidence when 
recommending that future Canadian cardiac pDCD should be 
undertaken under the supervision of a clinical trial or innova-
tive therapy program.
Neonatal DCD
Good Practice Statements.
47) Unless otherwise stated, the above GPSs and actionable 
recommendations that apply to infants and children 
should also apply to neonates, provided expertise in neo-
natal EOL care can be provided.
48) Diagnoses such as anencephaly or other similar severe, life-
limiting neurologic disorders, for whom NDD is impossi-
ble, do not preclude consideration as potential candidates 
for pDCD.
49) Centers not providing pDCD should establish a clear pro-
cess for transfer to hospitals with pDCD programs includ-
ing consideration of transfer of the mother of the patient 
who is a potential donor, ongoing provision of EOL care, 
limitation of economic burden on surrogate decision 
makers, and repatriation of the body.
Justification. In general, we felt that there are more simi-
larities than differences between neonatal and pediatric DCD 
practice. As with all potential DCD donors, optimal EOL care 
should remain the fundamental concern in a neonatal pDCD 
process. The particular relational and ethical aspects of neo-
natal death require the expertise of a clinician trained to deal 
with these EOL issues (80, 81). Also, even less is known about 
the rate of the dying process after WLST in neonates and how 
that might affect completion of pDCD in this population, 
which should be discussed with surrogates during the consent 
process.
One of the potential differences between neonatal and other 
populations is the relatively large numbers of regional, nonter-
tiary NICUs that do not offer pDCD (compared with relatively 
small number of PICUs) in which many potential neonatal 
pDCD donors may be initially hospitalized. If parents of chil-
dren hospitalized in NICUs that do not offer pDCD wish to 
pursue pDCD, clear protocols for transfer would be necessary, 
including consideration that the mother might not yet be eli-
gible for transfer or discharge (82).
We recommend that pDCD can be offered to patients born 
with anencephaly or other similar severe, life-limiting neuro-
logic disorders. In 2016, the Canadian Paediatric Society reaf-
firmed its position statement (83) that recommends against 
allowing deceased organ donation in this population based on 
the impossibility to complete a NDD examination in the set-
ting of a functional brain stem. This statement, however, was 
based solely on NDD. Since pDCD is unaffected by the fact 
that these patients do not fulfill NDD criteria, we recommend 
that pDCD can be offered to the substitute decision makers of 
patients born with this condition.
pDCD Implementation and Oversight
Good Practice Statements.
50) pDCD programs should seek out formal institutional 
approval within the existing hospital reporting structure.
51) There should be an integrated, collaborative approach 
to pDCD implementation with all hospital stakeholders, 
family and/or public partners, regional ODOs, and trans-
plant programs.
52) Local coroners should be contacted early in the process of 
developing local pDCD procedures.
53) Communication and education of staff should be consid-
ered a priority during the development and implementa-
tion of a pDCD protocol.
54) pDCD case management review, including regular debrief-
ing and a periodic quality assurance process, should occur.
55) Support for healthcare professionals involved in pDCD 
should be provided.
Justification. The establishment of a pDCD program should 
involve multidisciplinary collaboration with oversight from 
appropriate local authorities. The need for communica-
tion and education of all involved stakeholders has also been 
broadly emphasized in recent publications and was a frequently 
expressed sentiment during our pDCD symposium (25, 81). 
Quality control for this low-frequency, high-impact event is 
critical for pDCD programs. This process should involve medi-
cal and ethical oversight, ideally with linkage to measures of 
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donor family experiences and transplant outcomes. Establish-
ing robust ethical oversight also decreases the potential impact 
of institutional bias toward organ donation. Organ donation 
and transplantation activity are often a high-profile endeavor 
within a healthcare system, and the positive exposure associ-
ated with these programs may lead to a perception that dona-
tion activity takes precedence over ethical safeguards. The 
recognition and mitigation of this source of potential conflict 
interest is an important aspect of maintaining professional and 
public trust in the donation system.
Although we do not provide specific recommendation for 
documentation, inherent in the quality assurance component 
of recommendation 54 is the assumption that the process of 
pDCD be well documented. We encourage teams developing 
pDCD practices to visit the Canadian Blood Services website 
link listed below to see sample clinical and administrative 
checklists as well as documentation tools.
CONCLUSION
These recommendations are the result of a 3-year devel-
opment process and represent the first pediatric-specific, 
national guideline governing pDCD practice. The process was 
transparent and based on the best available evidence that was 
synthesized into recommendations using the most rigorous 
methods possible. Review of this literature highlighted several 
knowledge gaps that hopefully will be addressed by further 
research in the field (5). For further information regarding our 
methods and the justifications behind our recommendations, 
please visit http://www.organsandtissues.ca/s/english-expert/
leading-practices-public-awareness-and-education for the full 
report in English and French, as well as tools to facilitate pDCD 
implementation. For questions regarding establishing a pDCD 
program, please contact Dr. Weiss or Canadian Blood Services.
Although no guideline can perfectly address all concerns 
held by all stakeholders, it is our sincere hope that application 
of these guidelines can increase the number of organs available 
to Canadians, while also offering the meaningful possibility of 
organ donation to families experiencing the loss of a child.
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